(Q52434928)
Statements
Adjuvant reactivity predicts survival in patients with "high-risk" primary malignant melanoma treated with systemic BCG. EORTC Malignant Melanoma Cooperative Group Writing Committee. (English)
A J Cochran
M E Buyse
F J Lejeune
E Macher
J Revuz
P Rümke
1 November 1981
28
5
543-550